The UK and US have finalized a important trade agreement that will ensure no duties on UK pharmaceutical products entering the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to raise spending on drugs through the National Health Service (NHS). This move guarantees that tariffs on these vital products will remain at zero for a timeframe of three years.
This agreement is in response to previous warnings to dramatically increase tariffs on branded drug imports, with figures floated up to one hundred percent.
"This arrangement between the United Kingdom strengthens the international landscape for new treatments and brings long-overdue balance to American-British pharmaceutical trade," an announcement noted.
Economic Significance
Drugs represent one of the Britain's most significant export categories to the US, which is by far the primary destination for leading UK drugmakers.
Trade data reveal that in the 12 months to the end of last September, the UK sold medicines worth £11.1bn to the US. This figure represented 17.4% of all goods exports in that span.
"This guarantee secures work, boosts capital expenditure and sets the stage for the UK to become a worldwide center for life sciences," a government official remarked.
Specific NHS Changes
The deal includes several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to increase total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must pay back to the NHS to control costs will be capped at 15%. Last year, refunds topped 20%.
Recent Tensions
The pact comes amid a ongoing row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
The disagreement were exacerbated by arguments that American consumers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been paused or cancelled, while multi-billion-dollar expansions have been pledged toward US facilities.
The Science Minister stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the previous ten-year period.
